{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:46:16Z","timestamp":1791215176028,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,11,10]],"date-time":"2016-11-10T00:00:00Z","timestamp":1478736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Genet"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1038\/jhg.2016.133","type":"journal-article","created":{"date-parts":[[2016,11,10]],"date-time":"2016-11-10T02:23:04Z","timestamp":1478744584000},"page":"167-174","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Comparative study of idursulfase beta and idursulfase in vitro and in vivo"],"prefix":"10.1038","volume":"62","author":[{"given":"Chihwa","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinwook","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yokyung","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyi-Jeong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaehyeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jongmun","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byoungju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eui-cheol","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,10]]},"reference":[{"key":"BFjhg2016133_CR1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1750-1172-8-42","volume":"8","author":"YB Sohn","year":"2013","unstructured":"Sohn, Y. B., Cho, S. Y., Park, S. W., Kim, S. J., Ko, A. R., Kwon, E. K. et al. Phase I\/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with Jmucopolysaccharidosis II (Hunter syndrome). Orphanet. J. Rare Dis. 8, 42 (2013).","journal-title":"Orphanet. J. Rare Dis."},{"key":"BFjhg2016133_CR2","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ymgme.2006.09.001","volume":"90","author":"J Muenzer","year":"2007","unstructured":"Muenzer, J., Gucsavas-Calikoglu, M., McCandless, S. E., Schuetz, T. J. & Kimura, A. A phase I\/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol. Genet. Metab. 90, 329\u2013337 (2007).","journal-title":"Mol. Genet. Metab."},{"key":"BFjhg2016133_CR3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","volume":"8","author":"J Muenzer","year":"2006","unstructured":"Muenzer, J., Wraith, J. E., Beck, M., Giugliani, R., Harmatz, P., Eng, C. M. et al. A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet. Med. 8, 465\u2013473 (2006).","journal-title":"Genet. Med."},{"key":"BFjhg2016133_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1042\/bj2710075","volume":"271","author":"J Bielicki","year":"1990","unstructured":"Bielicki, J., Freeman, C., Clements, P. R. & Hopwood, J. J. Human liver iduronate-2-sulphatase. Purification, characterization and catalytic properties. Biochem. J. 271, 75\u201386 (1990).","journal-title":"Biochem. J."},{"key":"BFjhg2016133_CR5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nrm1050","volume":"4","author":"P Ghosh","year":"2003","unstructured":"Ghosh, P., Dahms, N. M. & Kornfeld, S. Mannose 6-phosphate receptors: new twists in the tale. Nat. Rev. Mol. Cell Biol. 4, 202\u2013212 (2003).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"BFjhg2016133_CR6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1146\/annurev.bi.61.070192.001515","volume":"61","author":"S Kornfeld","year":"1992","unstructured":"Kornfeld, S. Structure and function of the mannose 6-phosphate\/insulinlike growth factor II receptors. Annu. Rev. Biochem. 61, 307\u2013330 (1992).","journal-title":"Annu. Rev. Biochem."},{"key":"BFjhg2016133_CR7","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1146\/annurev.cb.05.110189.002411","volume":"5","author":"S Kornfeld","year":"1989","unstructured":"Kornfeld, S. & Mellman, I. The biogenesis of lysosomes. Annu. Rev. Cell Biol. 5, 483\u2013525 (1989).","journal-title":"Annu. Rev. Cell Biol."},{"key":"BFjhg2016133_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0092-8674(95)90314-3","volume":"82","author":"B Schmidt","year":"1995","unstructured":"Schmidt, B., Selmer, T., Ingendoh, A. & von Figura, K. A novel amino acid modification in sulfatases that is defective in multiple sulfatase deficiency. Cell 82, 271\u2013278 (1995).","journal-title":"Cell"},{"key":"BFjhg2016133_CR9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1432-1033.1996.0341z.x","volume":"238","author":"T Selmer","year":"1996","unstructured":"Selmer, T., Hallmann, A., Schmidt, B., Sumper, M. & von Figura, K. The evolutionary conservation of a novel protein modification, the conversion of cysteine to serinesemialdehyde in arylsulfatase from Volvox carteri. Eur. J. Biochem. 238, 341\u2013345 (1996).","journal-title":"Eur. J. Biochem."},{"key":"BFjhg2016133_CR10","doi-asserted-by":"publisher","first-page":"11963","DOI":"10.1073\/pnas.94.22.11963","volume":"94","author":"T Dierks","year":"1997","unstructured":"Dierks, T., Schmidt, B. & von Figura, K. Conversion of cysteine to formylglycine: a protein modification in the endoplasmic reticulum. Proc. Natl Acad. Sci. USA 94, 11963\u201311968 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFjhg2016133_CR11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1042\/bj3260243","volume":"326","author":"G Millat","year":"1997","unstructured":"Millat, G., Froissart, R., Maire, I. & Bozon, D. Characterization of iduronate sulphatase mutants affecting N-glycosylation sites and the cysteine-84 residue. Biochem. J. 326, 243\u2013247 (1997).","journal-title":"Biochem. J."},{"key":"BFjhg2016133_CR12","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ymgme.2007.03.003","volume":"91","author":"AR Garcia","year":"2007","unstructured":"Garcia, A. R., DaCosta, J. M., Pan, J., Muenzer, J. & Lamsa, J. C. Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II. Mol. Genet. Metab. 91, 183\u2013190 (2007).","journal-title":"Mol. Genet. Metab."},{"key":"BFjhg2016133_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13023-015-0356-0","volume":"10","author":"SY Cho","year":"2015","unstructured":"Cho, S. Y., Lee, J., Ko, A. R., Kwak, M. J., Kim, S., Sohn, Y. B. et al. Effect of systemic high dose enzyme replacement therapy on the improvement of CNS defects in a mouse model of mucopolysaccharidosis type II. Orphanet. J. Rare Dis. 10, 141 (2015).","journal-title":"Orphanet. J. Rare Dis."},{"key":"BFjhg2016133_CR14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ymgme.2011.02.018","volume":"103","author":"BK Burton","year":"2011","unstructured":"Burton, B. K. & Whiteman, D. A. Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS). Mol. Genet. Metab. 103, 113\u2013120 (2011).","journal-title":"Mol. Genet. Metab."},{"key":"BFjhg2016133_CR15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ymgme.2009.08.006","volume":"99","author":"T Okuyama","year":"2010","unstructured":"Okuyama, T., Tanaka, A., Suzuki, Y., Ida, H., Tanaka, T., Cox, G. F. et al. Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II). Mol. Genet. Metab. 99, 18\u201325 (2010).","journal-title":"Mol. Genet. Metab."},{"key":"BFjhg2016133_CR16","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/all.12155","volume":"68","author":"J Kim","year":"2013","unstructured":"Kim, J., Park, M. R., Kim, D. S., Lee, J. O., Maeng, S. H., Cho, S. Y. et al. IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome. Allergy 68, 796\u2013802 (2013).","journal-title":"Allergy"},{"key":"BFjhg2016133_CR17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10719-014-9523-0","volume":"31","author":"YK Chung","year":"2014","unstructured":"Chung, Y. K., Sohn, Y. B., Sohn, J. M., Lee, J., Chang, M. S., Kwun, Y. et al. A biochemical and physicochemical comparison of two recombinant enzymes used for enzyme replacement therapies of hunter syndrome. Glycoconj. J. 31, 309\u2013315 (2014).","journal-title":"Glycoconj. J."},{"key":"BFjhg2016133_CR18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.1399-0004.2011.01641.x","volume":"81","author":"YB Sohn","year":"2012","unstructured":"Sohn, Y. B., Ki, C. S., Kim, C. H., Ko, A. R., Yook, Y. J., Lee, S. J. et al. Identification of 11 novel mutations in 49 Korean patients with mucopolysaccharidosis type II. Clin. Genet. 81, 185\u2013190 (2012).","journal-title":"Clin. Genet."},{"key":"BFjhg2016133_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10059-010-0083-2","volume":"30","author":"SC Jung","year":"2010","unstructured":"Jung, S. C., Park, E. S., Choi, E. N., Kim, C. H., Kim, S. J. & Jin, D. K. Characterization of a novel mucopolysaccharidosis type II mouse model and recombinant AAV2\/8 vector-mediated gene therapy. Mol. Cells 30, 13\u201318 (2010).","journal-title":"Mol. Cells"},{"key":"BFjhg2016133_CR20","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1159\/000327532","volume":"195","author":"G Baldo","year":"2012","unstructured":"Baldo, G., Quoos Mayer, F., Burin, M., Carrillo-Farga, J., Matte, U. & Giugliani, R. Recombinant encapsulated cells overexpressing alpha-L-iduronidase correct enzyme deficiency in human mucopolysaccharidosis type I cells. Cells Tissues Organs 195, 323\u2013329 (2012).","journal-title":"Cells Tissues Organs"},{"key":"BFjhg2016133_CR21","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1006\/prep.2000.1230","volume":"19","author":"KW Zhao","year":"2000","unstructured":"Zhao, K. W. & Neufeld, E. F. Purification and characterization of recombinant human alpha-N-acetylglucosaminidase secreted by Chinese hamster ovary cells. Protein Exp. Purif. 19, 202\u2013211 (2000).","journal-title":"Protein Exp. Purif."},{"key":"BFjhg2016133_CR22","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/bab.52","volume":"58","author":"BL Tippin","year":"2011","unstructured":"Tippin, B. L., Troitskaya, L., Kan, S. H., Todd, A. K., Le, S. Q. & Dickson, P. I. Biochemical characterization of fluorescent-labeled recombinant human alpha-L-iduronidase in vitro. Biotechnol. Appl. Biochem. 58, 391\u2013396 (2011).","journal-title":"Biotechnol. Appl. Biochem."},{"key":"BFjhg2016133_CR23","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1006\/abio.1993.1197","volume":"210","author":"S Bjornsson","year":"1993","unstructured":"Bjornsson, S. Simultaneous preparation and quantitation of proteoglycans by precipitation with alcian blue. Anal. Biochem. 210, 282\u2013291 (1993).","journal-title":"Anal. Biochem."},{"key":"BFjhg2016133_CR24","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.ymthe.2004.10.006","volume":"11","author":"H Kobayashi","year":"2005","unstructured":"Kobayashi, H., Carbonaro, D., Pepper, K., Petersen, D., Ge, S., Jackson, H. et al. Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector. Mol. Ther. 11, 776\u2013789 (2005).","journal-title":"Mol. Ther."},{"key":"BFjhg2016133_CR25","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1007\/s11095-005-8177-9","volume":"22","author":"S Hermeling","year":"2005","unstructured":"Hermeling, S., Aranha, L., Damen, J. M., Slijper, M., Schellekens, H., Crommelin, D. J. et al. Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b. Pharm. Res. 22, 1997\u20132006 (2005).","journal-title":"Pharm. Res."},{"key":"BFjhg2016133_CR26","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1093\/hmg\/ddi364","volume":"14","author":"S Tomatsu","year":"2005","unstructured":"Tomatsu, S., Gutierrez, M., Nishioka, T., Yamada, M., Yamada, M., Tosaka, Y. et al. Development of MPS IVA mouse (Galnstm(hC79S.mC76S)slu) tolerant to human N-acetylgalactosamine-6-sulfate sulfatase. Hum. Mol. Genet. 14, 3321\u20133335 (2005).","journal-title":"Hum. Mol. Genet."},{"key":"BFjhg2016133_CR27","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1002\/jps.23663","volume":"102","author":"V Bi","year":"2013","unstructured":"Bi, V., Jawa, V., Joubert, M. K., Kaliyaperumal, A., Eakin, C., Richmond, K. et al. Development of a human antibody tolerant mouse model to assess the immunogenicity risk due to aggregated biotherapeutics. J. Pharm. Sci. 102, 3545\u20133555 (2013).","journal-title":"J. Pharm. Sci."},{"key":"BFjhg2016133_CR28","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1042\/BJ20061783","volume":"403","author":"A Fraldi","year":"2007","unstructured":"Fraldi, A., Biffi, A., Lombardi, A., Visigalli, I., Pepe, S., Settembre, C. et al. SUMF1 enhances sulfatase activities in vivo in five sulfatase deficiencies. Biochem. J. 403, 305\u2013312 (2007).","journal-title":"Biochem. J."},{"key":"BFjhg2016133_CR29","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/bit.20997","volume":"95","author":"FA Ngantung","year":"2006","unstructured":"Ngantung, F. A., Miller, P. G., Brushett, F. R., Tang, G. L. & Wang, D. I. RNA interference of sialidase improves glycoprotein sialic acid content consistency. Biotechnol. Bioeng. 95, 106\u2013119 (2006).","journal-title":"Biotechnol. Bioeng."},{"key":"BFjhg2016133_CR30","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1182\/blood.V73.1.84.84","volume":"73","author":"MN Fukuda","year":"1989","unstructured":"Fukuda, M. N., Sasaki, H., Lopez, L. & Fukuda, M. Survival of recombinant erythropoietin in the circulation: the role of carbohydrates. Blood 73, 84\u201389 (1989).","journal-title":"Blood"},{"key":"BFjhg2016133_CR31","first-page":"169","volume":"300","author":"P Weiss","year":"1989","unstructured":"Weiss, P. & Ashwell, G. The asialoglycoprotein receptor: properties and modulation by ligand. Prog. Clin. Biol. Res. 300, 169\u2013184 (1989).","journal-title":"Prog. Clin. Biol. Res."},{"key":"BFjhg2016133_CR32","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/glycob\/cwm017","volume":"17","author":"AJ Jones","year":"2007","unstructured":"Jones, A. J., Papac, D. I., Chin, E. H., Keck, R., Baughman, S. A., Lin, Y. S. et al. Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys. Glycobiology 17, 529\u2013540 (2007).","journal-title":"Glycobiology"},{"key":"BFjhg2016133_CR33","volume-title":"GeneReviews (R)","author":"M Scarpa","year":"1993","unstructured":"Scarpa, M. in GeneReviews (R) (eds Pagon R. A. et al.) (University of Washington, Seattle: Seattle, WA, USA, 1993\u20132016)."},{"key":"BFjhg2016133_CR34","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ymgme.2014.12.001","volume":"114","author":"S Tomatsu","year":"2015","unstructured":"Tomatsu, S., Almeciga-Diaz, C. J., Montano, A. M., Yabe, H., Tanaka, A., Dung, V. C. et al. Therapies for the bone in mucopolysaccharidoses. Mol. Genet. Metab. 114, 94\u2013109 (2015).","journal-title":"Mol. Genet. Metab."},{"key":"BFjhg2016133_CR35","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/1750-1172-8-101","volume":"8","author":"M Raluy-Callado","year":"2013","unstructured":"Raluy-Callado, M., Chen, W. H., Whiteman, D. A., Fang, J. & Wiklund, I. The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life. Orphanet. J. Rare Dis. 8, 101 (2013).","journal-title":"Orphanet. J. Rare Dis."},{"key":"BFjhg2016133_CR36","doi-asserted-by":"publisher","first-page":"vi3","DOI":"10.1093\/ndt\/gfh1092","volume":"20","author":"H Schellekens","year":"2005","unstructured":"Schellekens, H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol. Dial. Transplant. 20 (Suppl 6): vi3\u2013vi9 (2005).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFjhg2016133_CR37","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.biotechadv.2007.01.005","volume":"25","author":"B Sharma","year":"2007","unstructured":"Sharma, B. Immunogenicity of therapeutic proteins. Part 1: impact of product handling. Biotechnol. Adv. 25, 310\u2013317 (2007).","journal-title":"Biotechnol. Adv."},{"key":"BFjhg2016133_CR38","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.biotechadv.2007.01.007","volume":"25","author":"B Sharma","year":"2007","unstructured":"Sharma, B. Immunogenicity of therapeutic proteins. Part 3: impact of manufacturing changes. Biotechnol. Adv. 25, 325\u2013331 (2007).","journal-title":"Biotechnol. Adv."},{"key":"BFjhg2016133_CR39","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nrd2804","volume":"8","author":"R Jefferis","year":"2009","unstructured":"Jefferis, R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat. Rev. Drug Discov. 8, 226\u2013234 (2009).","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/jhg2016133.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/jhg2016133","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/jhg2016133.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:35:19Z","timestamp":1684416919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/jhg2016133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,10]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["BFjhg2016133"],"URL":"https:\/\/doi.org\/10.1038\/jhg.2016.133","relation":{},"ISSN":["1434-5161","1435-232X"],"issn-type":[{"value":"1434-5161","type":"print"},{"value":"1435-232X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,10]]},"assertion":[{"value":"7 July 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}